J Korean Ophthalmol Soc.  2016 Sep;57(9):1415-1421. 10.3341/jkos.2016.57.9.1415.

Long-term Results of Selective Laser Trabeculoplasty versus Latanoprost or Dorzolamide/Timolol Fixed Combination

• Lim JH
• Kim DG
• Cho SH
• Hong YJ

• KMID: 2351872
• DOI: http://doi.org/10.3341/jkos.2016.57.9.1415

Abstract

PURPOSE
To compare the efficacy of selective laser trabeculoplasty (SLT) in patients treated with either latanoprost or dorzolamide/timolol fixed combination (DTFC) for primary open-angle glaucoma.
METHODS
This retrospective study included 92 consecutive patients who underwent a 180-degree SLT for the first time. The subjects divided into two groups:patients who received latanoprost (n = 63) or DTFC (n = 29) before and after SLT. The main outcome measure was intraocular pressure (IOP) decrease over five years after SLT. The mean IOP change, mean percentage of IOP reduction, and success rates were compared between the patients treated with latanoprost and the patients treated with DTFC. Success was defined as an IOP decrease ≥ 3 mm Hg or IOP reduction ≥ 20% without additional medications, laser surgery, or glaucoma surgery.
RESULTS
At the postoperative one-year follow-up, the mean IOP was 15.7 ± 2.2 mm Hg in the latanoprost group and, 16.2 ± 2.4 mm Hg in the DTFC group. At the postoperative five-year follow-up, the mean IOP was 15.1 ± 2.5 mm Hg in the latanoprost group and, 14.6 ± 1.7 mm Hg in the DTFC group. There were no statistically significant differences in IOP change, percentage IOP reduction, or success rate between the groups at each time point after the SLT (p > 0.05).
CONCLUSIONS
Selective laser trabeculoplasty showed a reasonable efficacy in lowering the IOP over a five-year follow-up period. There were no significant differences in IOP lowering effect or success rate between the patients treated with latanoprost or DTFC.

Keyword

Dorzolamide/Timolol fixed combination; Intraocular pressure; Latanoprost; Selective laser trabeculoplasty

MeSH Terms

Follow-Up Studies
Glaucoma
Glaucoma, Open-Angle
Humans
Intraocular Pressure
Laser Therapy
Outcome Assessment (Health Care)
Retrospective Studies
Trabeculectomy*

Figure

• 

  Figure 1. The intraocular pressure (IOP) profile before and after the selective laser trabeculoplasty. The numbers on the graph indicated the p-value at each time point. The p-value was calculated via the Student's t-test. LP = latanoprost; DTFC = dorzolamide/timolol fixed combination.

• 

  Figure 2. The mean change in pressure from the pre-treatment intraocular pressure (PreIOP) for latanoprost (LP) and dorzolamide/timolol fixed combination (DTFC). The numbers on the graph indicated the p-value at each time point. The p-value was calculated via the Student's t-test.

• 

  Figure 3. The Kaplan-Meier chart for latanoprost (LP) and dorzolamide-timolol fixed combination (DTFC) using the definition of success. There were not statistically significant differences between the survival curves in the follow-up period (Logrank test, p ＝ 0.235).

Reference

References

1. Anderson RR, Parrish JA. Selective photothermolysis: precise mi-crosurgery by selective absorption of pulsed radiation. Science. 1983; 220:524–7.

2. Juzych MS, Chopra V, Banitt MR, et al. Comparison of long-term outcomes of selective laser trabeculoplasty versus argon laser abdominal in open-angle glaucoma. Ophthalmology. 2004; 111:1853–9.

3. McIlraith I, Strasfeld M, Colev G, Hutnik CM. Selective laser abdominal as initial and adjunctive treatment for open-angle glaucoma. J Glaucoma. 2006; 15:124–30.

4. Realini T. Selective laser trabeculoplasty: a review. J Glaucoma. 2008; 17:497–502.

5. Sihota R. Lasers in primary open angle glaucoma. Indian J Ophthalmol. 2011; 59(Suppl):S114–7.

6. Melamed S, Ben Simon GJ, Levkovitch-Verbin H. Selective laser trabeculoplasty as primary treatment for open-angle glaucoma: a prospective, nonrandomized pilot study. Arch Ophthalmol. 2003; 121:957–60.

7. Shazly TA, Smith J, Latina MA. abdominal safety and efficacy of selective laser trabeculoplasty as primary therapy for the treatment of pseudoexfoliation glaucoma compared with primary open-angle glaucoma. Clin Ophthalmol. 2010; 5:5–10.

8. Scherer WJ. Effect of topical prostaglandin analog use on outcome following selective laser trabeculoplasty. J Ocul Pharmacol Ther. 2007; 23:503–12.

9. Song J, Lee PP, Epstein DL, et al. High failure rate associated with 180 degrees selective laser trabeculoplasty. J Glaucoma. 2005; 14:400–8.

10. Singh D, Coote MA, O'Hare F, et al. Topical prostaglandin analogues do not affect selective laser trabeculoplasty outcomes. Eye (Lond). 2009; 23:2194–9.

11. Kara N, Altan C, Satana B, et al. Comparison of selective laser abdominal success in patients treated with either prostaglandin or timolol/dorzolamide fixed combination. J Ocul Pharmacol Ther. 2011; 27:339–42.

12. Bron AM, Emmerich KH. Latanoprost versus combined timolol and dorzolamide. Surv Ophthalmol. 2002; 47(Suppl 1):S148–54.

13. The Advanced Glaucoma Intervention Study (AGIS): 7. The relationship between control of intraocular pressure and visual field deterioration. The AGIS Investigators. Am J Ophthalmol. 2000; 130:429–40.

14. Lichter PR, Musch DC, Gillespie BW, et al. Interim clinical abdominals in the Collaborative Initial Glaucoma Treatment Study abdominal initial treatment randomized to medications or surgery. Ophthalmology. 2001; 108:1943–53.

15. Kass MA, Heuer DK, Higginbotham EJ, et al. The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol. 2002; 120:701–13. discussion 829–30.

16. Heijl A, Leske MC, Bengtsson B, et al. Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial. Arch Ophthalmol. 2002; 120:1268–79.

17. Kramer TR, Noecker RJ. Comparison of the morphologic changes after selective laser trabeculoplasty and argon laser trabeculoplasty in human eye bank eyes. Ophthalmology. 2001; 108:773–9.

18. Alvarado JA, Murphy CG. Outflow obstruction in pigmentary and primary open angle glaucoma. Arch Ophthalmol. 1992; 110:1769–78.

19. Hodge WG, Damji KF, Rock W, et al. Baseline IOP predicts abdominal laser trabeculoplasty success at 1 year post-treatment: results from a randomised clinical trial. Br J Ophthalmol. 2005; 89:1157–60.

20. Lai JS, Chua JK, Tham CC, Lam DS. Five-year follow up of abdominal laser trabeculoplasty in Chinese eyes. Clin Experiment Ophthalmol. 2004; 32:368–72.

21. Martow E, Hutnik CM, Mao A. SLT and adjunctive medical abdominal: a prediction rule analysis. J Glaucoma. 2011; 20:266–70.

22. Lindsey JD, Kashiwagi K, Boyle D, et al. Prostaglandins increase proMMP-1 and proMMP-3 secretion by human ciliary smooth muscle cells. Curr Eye Res. 1996; 15:869–75.

23. Lindsey JD, Kashiwagi K, Kashiwagi F, Weinreb RN. Prostaglandins alter extracellular matrix adjacent to human ciliary muscle cells in vitro. Invest Ophthalmol Vis Sci. 1997; 38:2214–23.

24. Coakes RL, Brubaker RF. The mechanism of timolol in lowering intraocular pressure. In the normal eye. Arch Ophthalmol. 1978; 96:2045–8.

25. Balfour JA, Wilde MI. Dorzolamide. A review of its pharmacology and therapeutic potential in the management of glaucoma and abdominal hypertension. Drugs Aging. 1997; 10:384–403.

26. Noecker RJ. The management of glaucoma and intraocular abdominal: current approaches and recent advances. Ther Clin Risk Manag. 2006; 2:193–206.

27. Lee JY, Lee YK, Moon JI, Park MH. abdominal outcomes and abdominal factors for success of selective laser trabeculoplasty. J Korean Ophthalmol Soc. 2014; 55:1347–54.